These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 9121154)

  • 1. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
    Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
    Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
    Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
    Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
    Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
    J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.
    Hosch SB; Scheunemann P; Lüth M; Inndorf S; Stoecklein NH; Erbersdobler A; Rehders A; Gundlach M; Knoefel WT; Izbicki JR
    J Gastrointest Surg; 2001; 5(6):673-9. PubMed ID: 12086907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization.
    Li Y; Parks GD
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29693588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
    Iborra A; Mayorga M; Llobet N; Martínez P
    Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM; Shuler C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.